KPTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KPTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Karyopharm Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $1.5 Mil. Karyopharm Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2023 was $3.1 Mil. Karyopharm Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.48.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Karyopharm Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 188.76.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Karyopharm Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.09.
The historical data trend for Karyopharm Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory Turnover | Get a 7-Day Free Trial | 6.96 | 1.81 | 1.01 | 1.25 | 1.36 |
Karyopharm Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Inventory Turnover | Get a 7-Day Free Trial | 0.44 | 0.34 | 0.32 | 0.27 | 0.48 |
Karyopharm Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 4.942 | / ( | (4.224 | + | 3.043) | / | 2 ) |
= | 4.942 | / | 3.6335 | ||||
= | 1.36 |
Karyopharm Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover (Q: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Dec. 2023 ) | / ( | (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) |
= | 1.486 | / ( | (3.105 | + | 3.043) | / | 2 ) |
= | 1.486 | / | 3.074 | ||||
= | 0.48 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (NAS:KPTI) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Karyopharm Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 3.074 | / | 1.486 | * | 365 / 4 | |
= | 188.76 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Karyopharm Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 3.074 | / | 33.747 | |
= | 0.09 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Karyopharm Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard A. Paulson | director, officer: President and CEO | 85 WELLS AVENUE, NEWTON MA 02459 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Michael Mason | officer: EVP, CFO, Treasurer | 300 3RD STREET, CAMBRIDGE MA 02142 |
Michael Mano | officer: SVP, General Counsel&Secretary | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Sohanya Roshan Cheng | officer: SVP Sales & Commercial Ops | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Zhen Su | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Stuart Poulton | officer: EVP, Chief Development Officer | 85 WELLS AVENUE, NEWTON MA 02459 |
Reshma Rangwala | officer: EVP & Chief Medical Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Stephen Mitchener | officer: SVP, Chief Business Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Ran Frenkel | officer: EVP, WW Development Operations | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459 |
Jatin Shah | officer: EVP, Chief Medical Officer | C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Sharon Shacham | officer: C.S.O & Pres. of Res & Develop | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael Kauffman | director, officer: President, C.E.O., C.M.O. | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
From GuruFocus
By PRNewswire • 01-08-2024
By PRNewswire • 09-01-2023
By PRNewswire PRNewswire • 04-14-2023
By PRNewswire PRNewswire • 05-01-2023
By PRNewswire • 08-01-2023
By PRNewswire • 09-05-2023
By PRNewswire PRNewswire • 05-04-2023
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire • 07-17-2023
By PRNewswire • 09-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.